10,643 results match your criteria Parkinson Disease Dementia


Mortality and Institutionalization After Percutaneous Endoscopic Gastrostomy in Parkinson's Disease and Related Conditions.

Mov Disord Clin Pract 2020 Jul 9;7(5):509-515. Epub 2020 Jun 9.

Department of Medicine for the Elderly, Royal Derby Hospital, University Hospitals of Derby and Burton Derby DE22 3NE United Kingdom.

Background: Percutaneous endoscopic gastrostomy (PEG) can facilitate feeding and medication administration in dysphagic patients with Parkinson's disease and related disorders. Information on survival, institutionalization, and complications post PEG might inform feeding decisions.

Method: A total of 93 patients with Parkinson's disease and related disorders were identified by review of PEG registers and by searching the administrative databases in 2 large UK university hospitals (2005-2017); 83 case notes were available for retrospective review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12971DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328413PMC

Faster Acquisition for Dopamine Transporter Imaging Using Swiftscan Step and Shoot Continuous SPECT Without Impairing Visual and Semiquantitative Analysis.

Front Med (Lausanne) 2020 18;7:235. Epub 2020 Jun 18.

Nuclear Medicine Department, CHRU TOURS, Hôpital Bretonneau, Tours, France.

Dopamine transporter (DAT) imaging with [123I] FP-CIT (DaTSCAN) is an established diagnostic tool in parkinsonism and dementia. Using a low energy high resolution and sensitivity (LEHRS) collimator and step and shoot continuous scanning mode, Swiftscan single photon emission computed tomography (SPECT) (GE Healthcare) enhances sensitivity and enables time or dose reduction. In this phantom and clinical study, we aim to validate a 25% reduction of the acquisition time using Swiftscan and its lack of effect on visual or quantitative analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2020.00235DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314987PMC

Patterns of striatal dopamine depletion in early Parkinson disease: Prognostic relevance.

Neurology 2020 Jul 2. Epub 2020 Jul 2.

From the Department of Neurology (S.J.C., H.S.Y., Y.H.L., P.H.L., Y.H.S.) and Biostatistics Collaboration Unit (H.S.L.), Yonsei University College of Medicine, Seoul, South Korea.

Objective: To investigate whether the patterns of striatal dopamine depletion on dopamine transporter (DAT) scans could provide information on the long-term prognosis in Parkinson disease (PD).

Methods: We enrolled 205 drug-naive patients with early-stage PD, who underwent F-FP-CIT PET scans at initial assessment and received PD medications for 3 or more years. After quantifying the DAT availability in each striatal subregion, factor analysis was conducted to simplify the identification of striatal dopamine depletion patterns and to yield 4 striatal subregion factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000009878DOI Listing

Dementia and subthalamic deep brain stimulation in Parkinson disease: A long-term overview.

Neurology 2020 Jul 1. Epub 2020 Jul 1.

From the Movement Disorders Unit (F.B., V.F., F.C., E.S., E.L., A.B., S.M., P.P., A.K., E.C., C.A., P.K., A.C., E.M.) and Neurosurgery Department (A.L.B., S.C., E.S.), CHU Grenoble Alpes, France; Institute of Neurology (F.B.), Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica Del Sacro Cuore, Rome, Italy; U1216 (V.F., E.S., E.L., A.B., S.M., P.P., A.K., E.C., C.A., P.K., A.L.B., S.C., E.S., A.C., E.M.), Grenoble Institut des Neurosciences, Inserm, Université Grenoble Alpes, France; Neurology Unit (F.C.), Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia; Clinical and Experimental Medicine PhD Program (F.C.), University of Modena and Reggio Emilia, Modena; Department of Clinical and Movement Neurosciences (P.L.), University College London Queen Square Institute of Neurology, UK; and Department of Neurology (P.K.), INSELSPITAL, University Hospital Bern, Switzerland.

Objectives: To assess the prevalence and the cumulative incidence of dementia at short-, medium- and long-term follow-up after deep brain stimulation (DBS) of the subthalamic nucleus (STN) (at 1, 5, and 10 years) and to evaluate potential risk factors for postoperative dementia.

Methods: The presence of dementia (according to the DSM-V) was retrospectively evaluated at each postoperative follow-up in patients with Parkinson disease (PD) who underwent bilateral STN-DBS. Preoperative and perioperative risk factors of developing postoperative dementia were also investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000009822DOI Listing

Experiences of advance care planning in Parkinson's disease and atypical Parkinsonian disorders: a mixed methods systematic review.

Eur J Neurol 2020 Jun 30. Epub 2020 Jun 30.

Department of Neurology, Institute of Neurology, UCL, London, U.K.

Background: Advance care planning allows people to plan for their future care needs and can include medical, psychological and social aspects. However, little is known on the use, experience of and attitudes towards advance care planning in patients with Parkinsonian disorders, their family carers and in health care professionals.

Methods: We conducted a systematic search of online databases in April 2019 using a narrative synthesis approach with thematic analysis and tabulation to synthesise the findings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ene.14424DOI Listing

Parkinson disease clinical subtypes: key features & clinical milestones.

Ann Clin Transl Neurol 2020 Jun 29. Epub 2020 Jun 29.

Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.

Objectives: Based on multi-domain classification of Parkinson disease (PD) subtypes, we sought to determine the key features that best differentiate subtypes and the utility of PD subtypes to predict clinical milestones.

Methods: Prospective cohort of 162 PD participants with ongoing, longitudinal follow-up. Latent class analysis (LCA) delineated subtypes based on score patterns across baseline motor, cognitive, and psychiatric measures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acn3.51102DOI Listing

REM sleep behavior disorder (RBD).

Authors:
Michele T Hu

Neurobiol Dis 2020 Jun 26:104996. Epub 2020 Jun 26.

Oxford Parkinson's Disease Centre, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, UK. Electronic address:

Since its first description in 1986 by Dr. Carlos Schenck, and his group's subsequent report of the delayed emergence of a Parkinsonian disorder in idiopathic RBD patients one decade later, RBD has emerged in recent years as one of the most promising markers of prodromal Parkinson's (References 2, 3). RBD is present in 25-58% of patients with Parkinson's disease and up to 90% of those with Dementia with Lewy Bodies (DLB) or Multiple System Atrophy (MSA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2020.104996DOI Listing

Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease-Reply.

Authors:
Charbel Moussa

JAMA Neurol 2020 Jun 29. Epub 2020 Jun 29.

Department of Neurology, Georgetown University Medical Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2020.1931DOI Listing

Electrophysiological differences in cortical excitability in different forms of dementia: A transcranial magnetic stimulation and laboratory biomarkers study.

Neurophysiol Clin 2020 Jun 23. Epub 2020 Jun 23.

Medical physiology department, faculty of medicine, Assiut university, Assiut, Egypt.

Background: The aim of the present study was to identify neurophysiologic markers to differentiate between Alzheimer dementia (AD), Vascular dementia (VaD), and Parkinson's disease dementia (PDD), and to examine their relationship to levels of transforming growth factor β1 (TGFβ1).

Methods: The study included 15 patients with each type of dementia (AD, VaD, PDD) and 25 control subjects. Dementia patients were diagnosed according to the DiagnosticandStatisticalManualofMentalDisorders4thedition-revised(DSM-IV-R). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neucli.2020.05.001DOI Listing

Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson's Disease and Adverse Effects of L-DOPA.

Front Neuroanat 2020 4;14:26. Epub 2020 Jun 4.

Laboratory of Cellular and Molecular Neurobiology of Parkinson's Disease, Research Center for Molecular Medicine and Chronic Diseases (CIMUS), Deptartment of Morphological Sciences, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela, Santiago de Compostela, Spain.

Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra. However, other non-dopaminergic neuronal systems such as the serotonergic system are also involved. Serotonergic dysfunction is associated with non-motor symptoms and complications, including anxiety, depression, dementia, and sleep disturbances. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fnana.2020.00026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289026PMC

Translation, Validation, Diagnostic Accuracy, and Reliability of Screening Questionnaire for Parkinsonism in Three African Countries.

J Parkinsons Dis 2020 Jun 18. Epub 2020 Jun 18.

Neurology Department, University Hospital, Burgos, Spain.

Background: Availability of validated Parkinson's disease (PD) questionnaires in languages spoken in Africa will enable the conduct of epidemiological studies.

Objective: The aims of the current study were to develop cross-cultural translated and validated Arabic and French versions of a PD screening questionnaire, and determine its diagnostic accuracy for recognition of parkinsonism in early and moderate-advanced PD in three countries (Cameroon (French), Egypt (Arabic), and Nigeria (English)).

Methods: This cross-sectional study screened159 participants (81 PD and 78 controls) using the PD screening questionnaire. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JPD-202040DOI Listing

A Prospective Validation of the Updated Movement Disorders Society Research Criteria for Prodromal Parkinson's Disease.

Mov Disord 2020 Jun 22. Epub 2020 Jun 22.

Parkinson's Disease and Movement Disorders Department, Hygeia Hospital, Athens, Greece.

Objective: The objective of this study was to validate the recently updated research criteria for prodromal Parkinson's disease (pPD) proposed by the International Parkinson's Disease and Movement Disorders Society.

Methods: A total of 16 of 21 markers of pPD were ascertained in the Hellenic Longitudinal Investigation of Aging and Diet cohort composed of community-dwelling individuals aged ≥65 years. The probability of pPD was calculated for 961 individuals without Parkinson's disease (PD) or dementia with Lewy bodies at baseline who were followed-up for a median of 3 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.28145DOI Listing

Potential for Treatment of Neurodegenerative Diseases with Natural Products or Synthetic Compounds that Stabilize Microtubules.

Curr Pharm Des 2020 Jun 21. Epub 2020 Jun 21.

Institute of Molecular and Translational Medicine, Faculty of Medicin U v H ěvo í á 5 77900 O omou . Czech Republic.

No effective therapeutics to treat neurodegenerative diseases exist, despite significant attempts to find drugs that can reduce or rescue the debilitating symptoms of tauopathies such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, amyotrophic lateral sclerosis, or Pick's disease. A number of in vitro and in vivo models exist for studying neurodegenerative diseases, including cell models employing induced-pluripotent stem cells, cerebral organoids, and animal models of disease. Recent research has focused on microtubule stabilizing agents, either natural products or synthetic compounds that can prevent the axonal destruction caused by tau protein pathologies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612826666200621171302DOI Listing

Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.

Ann Neurol 2020 Jun 18. Epub 2020 Jun 18.

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Objective: To explore the role of alpha-synuclein (αSyn) oligomers and neurofilament light chain (NFL) in cerebrospinal fluid (CSF) as markers of early multiple system atrophy (MSA) and to contrast findings to Lewy body synucleinopathies.

Methods: In a discovery cohort of well-characterized early MSA patients (n = 24) and matched healthy controls (CON, n = 14) we utilized ELISA to measure NFL and protein misfolding cyclic amplification (PMCA) to detect αSyn oligomers in CSF. We confirmed findings in a separate prospectively enrolled cohort of patients with early MSA (n = 38), Parkinson's disease (PD, n = 16), dementia with Lewy bodies (DLB, n = 13), and CON subjects (n = 15). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.25824DOI Listing

Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset.

Mov Disord 2020 Jun 18. Epub 2020 Jun 18.

Liggins Institute, The University of Auckland, Auckland, New Zealand.

Background: GBA mutations are numerically the most significant genetic risk factor for Parkinson's disease (PD), yet these mutations have low penetrance, suggesting additional mechanisms.

Objectives: The objective of this study was to determine if the penetrance of GBA in PD can be explained by regulatory effects on GBA and modifier genes.

Methods: Genetic variants associated with the regulation of GBA were identified by screening 128 common single nucleotide polymorphisms (SNPs) in the GBA locus for spatial cis-expression quantitative trail locus (supported by chromatin interactions). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.28144DOI Listing

Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson's Disease.

Am J Geriatr Psychiatry 2020 May 18. Epub 2020 May 18.

Department of Neurology, University of Pennsylvania Perelman School of Medicine, (DSA, TPPN, DW, AWW), Philadelphia, PA; Department of Neurology Translational Center for Excellence for Neuroepidemiology and Neurological Outcomes Research, University of Pennsylvania Perelman School of Medicine, (DSA, TPPN, AWW), Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, (DSA, TPPN, SH, DX, AWW), Philadelphia, PA; Department of Biostatics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, (DSA, TPPN, SH, DX, AWW), Philadelphia, PA.

Objective: To examine the national prevalence of pharmacological treatment of affective disorders in older adults with Parkinson's disease (PD), and determine the prevalence and risk factors for receipt of an American Geriatrics Society Beers Criteria® defined potentially inappropriate medication (PIM) for affective disorder treatment.

Design: Cross-sectional analysis of 2014 Medicare data.

Setting: Research Identifiable File data from the Centers for Medicare and Medicaid Services. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jagp.2020.05.014DOI Listing

Skin Cancer May Delay Onset but Not Progression of Parkinson's Disease: A Nested Case-Control Study.

Front Neurol 2020 28;11:406. Epub 2020 May 28.

Department of Neurology, James J. and Joan A. Gardner Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH, United States.

To evaluate the extent to which cancer, a biological opposite to neurodegenerative disorders, may affect the onset and progression of Parkinson's disease (PD). A nested case-control design in consecutive PD patients with (cases) vs. without (controls) cancer was used to compare time to clinical diagnosis and time to Hoehn & Yahr (H&Y) staging score ≥ 3 as a measure of progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2020.00406DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270344PMC

Predicting Phenoconversion in Pure Autonomic Failure.

Neurology 2020 Jun 16. Epub 2020 Jun 16.

Department of Neurology, Mayo Clinic, Rochester, MN

Objective: To determine predicting factors and frequency of phenoconversion from pure autonomic failure (PAF) into a synucleinopathy with motor or cognitive involvement of multiple system atrophy (MSA), Parkinson disease (PD), or dementia with Lewy bodies (DLB).

Methods: We performed a retrospective review of all PAF patients from 2001-2011 evaluated at Mayo Clinic, Rochester. Clinical follow-up and patient telephone calls were used to assess for development of symptoms and diagnosis of MSA, PD or DLB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000010002DOI Listing

TDP-1/TDP-43 potentiates human α-Synuclein (HASN) neurodegeneration in Caenorhabditis elegans.

Biochim Biophys Acta Mol Basis Dis 2020 Jun 9;1866(10):165876. Epub 2020 Jun 9.

Centre for Reproduction, Development and Aging, Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa 999078, Macau SAR, China. Electronic address:

TAR DNA binding protein (TDP-43) is a DNA/RNA binding protein whose pathological role in amyotrophic lateral sclerosis (ALS) and frontal temporal lobe dementia (FTLD) via formation of protein aggregates is well established. In contrast, knowledge concerning its interactions with other neuropathological aggregating proteins is poorly understood. Human α-synuclein (HASN) elicits dopaminergic neuron degeneration via protein aggregation in Parkinson's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbadis.2020.165876DOI Listing
June 2020
4.882 Impact Factor

Protective Effects of Polydatin Against Dementia-Related Disorders.

Authors:
Kim San Tang

Curr Neuropharmacol 2020 Jun 11. Epub 2020 Jun 11.

School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor. Malaysia.

Dementia is a collection of symptoms affecting a person's cognition. Dementia is debilitating, and therefore, finding an effective treatment is of the utmost importance. Resveratrol, which exhibits neuroprotective effects, has low bioavailability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1570159X18666200611144825DOI Listing

Altered awareness of motor symptoms in Parkinson's disease and Dementia with Lewy Bodies: a systematic review.

Int J Geriatr Psychiatry 2020 Jun 11. Epub 2020 Jun 11.

Edinburgh Dementia Prevention, University of Edinburgh, Edinburgh, UK.

Objectives: Altered awareness of motor symptoms is reported in people with Parkinson's disease and Dementia with Lewy Bodies, and may adversely affect quality of life and medication concordance. How symptom awareness is influenced by motor and cognitive disease severity, age and medication use is not fully understood. We carried out a systematic review of the literature on motor symptom awareness in Parkinson's disease and Dementia with Lewy Bodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gps.5362DOI Listing

GP awareness, practice, knowledge and confidence: evaluation of the first nation-wide dementia-focused continuing medical education program in Australia.

BMC Fam Pract 2020 Jun 10;21(1):104. Epub 2020 Jun 10.

Dementia Centre for Research Collaboration, University of New South Wales (UNSW) Sydney, AGSM Building, Sydney, NSW, 2052, Australia.

Background: Dementia is under-diagnosed in primary care. Timely diagnosis and care management improve outcomes for patients and caregivers. This research evaluated the effectiveness of a nationwide Continuing Medical Education (CME) program to enhance dementia-related awareness, practice, knowledge and confidence of general practitioners (GPs) in Australia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12875-020-01178-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285709PMC
June 2020
1.735 Impact Factor

Subjective Cognitive Complaint in Parkinson's Disease Patients with Normal Cognition: Canary in the Coal Mine?

Mov Disord 2020 Jun 10. Epub 2020 Jun 10.

Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.

Objective: The objective of this study was to determine the frequency and impact of subjective cognitive complaint (SCC) in Parkinson's disease (PD) patients with normal cognition.

Methods: Patients with PD with expert consensus-determined normal cognition at baseline were asked a single question regarding the presence of SCC. Baseline (N = 153) and longitudinal (up to 4 follow-up visits during a 5-year period; N = 121) between-group differences in patients with PD with (+SCC) and without (-SCC) cognitive complaint were examined, including cognitive test performance and self-rated and informant-rated functional abilities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.28115DOI Listing

Pneumonia risk and its associated factors in Parkinson's disease: A National Database Study.

J Neurol Sci 2020 May 29;415:116949. Epub 2020 May 29.

Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea. Electronic address:

Background: Despite pneumonia being an emerging burden on Parkinson's disease patients, there is essentially nothing known on whether they are at an increased risk of pneumonia occurrence and their associated factors.

Objectives: To determine whether Parkinson's disease is associated with the risk of pneumonia and its associated factors.

Methods: Using nationwide database that covers the whole population in South Korea from 2002 to 2017, we identified newly diagnosed Parkinson's disease patients in 2004-2006, and selected four age- and sex-matched controls for each patient from the general population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2020.116949DOI Listing

Transglutaminase 2 Depletion Attenuates α-Synuclein Mediated Toxicity in Mice.

Neuroscience 2020 Jun 2;441:58-64. Epub 2020 Jun 2.

Robert Wood Johnson Medical School Institute for Neurological Therapeutics, and Department of Neurology, Rutgers Biomedical and Health Sciences, Piscataway, NJ 08854, USA. Electronic address:

α-Synuclein (α-Syn) is a key pathogenic protein in α-synucleinopathies including Parkinson disease (PD) and Dementia with Lewy Bodies. The aggregation of α-Syn is believed to be deleterious and a critical step leading to neuronal dysfunction and death. One of the factors that may contribute to the initial steps of this aggregation is crosslinking through transglutaminase 2 (TG2). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuroscience.2020.05.047DOI Listing

Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review.

Parkinsonism Relat Disord 2020 May 25;75:55-62. Epub 2020 May 25.

Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address:

There is a considerable overlap between Parkinson's Disease Dementia (PDD) and Dementia with Lewy Bodies (DLB). They present a challenge therapeutically, with regard to morbidity and mortality risk. In particular, symptoms of psychosis in these conditions augur a considerably increased burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2020.05.026DOI Listing

Infections or Sepsis Preceding Clinically Diagnosed α-Synucleinopathies: A Case-Control Study.

Mov Disord 2020 Jun 1. Epub 2020 Jun 1.

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Background: Several studies have proposed a role for infections to induce an inflammatory response triggering Parkinson's disease. This remains controversial and the influence of severe infections on other α-synucleinopathies (Dementia with Lewy Bodies, Parkinson's disease dementia, and Multiple System Atrophy) has not been adequately investigated.

Objectives: To assess the association between hospitalization-required infections or sepsis and risk of clinically diagnosed α-synucleinopathies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.28111DOI Listing

Characterization of recessive Parkinson's disease in a large multicenter study.

Ann Neurol 2020 May 30. Epub 2020 May 30.

Research Unit UMR_1127 at Sorbonne Université, Paris, France.

Studies of the phenotype and population distribution of rare genetic forms of parkinsonism are required, now that gene-targeting approaches for Parkinson's disease have reached the clinical trial stage. We evaluated the frequencies of PRKN, PINK1, and DJ-1 mutations in a cohort of 1587 cases. Mutations were found in 14. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.25787DOI Listing

Accumulation of HAX-1 and PARL in brainstem- and cortical-type Lewy bodies in Parkinson's disease and dementia with Lewy bodies.

J Neurol Sci 2020 May 20;415:116928. Epub 2020 May 20.

Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

HS1-associated protein X-1 (HAX-1) and presenilin-associated rhomboid-like protein (PALR) were reported to play an important role in the activation of HtrA2/Omi, which is also designated PARK13, in the mitochondria. To elucidate the role of HAX-1 and PARL in patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB), we performed immunohistochemical studies on HtrA2/Omi, HAX-1 and PARL using autopsied brains from 8 normal subjects, 10 patients with PD and 5 patients with DLB. In accordance with our previous report, brainstem-type and cortical Lewy bodies were strongly immunopositive for HtrA2/Omi. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2020.116928DOI Listing

Sporadic Creutzfeldt-Jakob Disease: Case Report and Literature Review.

Cureus 2020 Apr 21;12(4):e7767. Epub 2020 Apr 21.

Neurology, Marcus Neuroscience Institute, Boca Raton Regional Hospital, Boca Raton, USA.

The proverbial "zebras" in neurology are often times missed due to their low prevalence and incidence in the community. The number of misdiagnoses and improper therapeutic interventions that occur are further increased when patients with these rare diseases present with signs and symptoms of more common disorders. One such disease is sporadic Creutzfeldt-Jakob disease (sCJD), a prion disease that causes neuronal derangement and classically presents as a rapidly progressing dementia with extrapyramidal signs, ataxia, behavioural problems, and myoclonus in the advanced stage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7767DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243655PMC

Progressive Parkinsonism Three Years after Shunt Surgery in a Patient with Idiopathic Normal Pressure Hydrocephalus.

Intern Med 2020 May 26. Epub 2020 May 26.

Shimada Hospital, Japan.

An 86-year-old man, who had undergone a lumboperitoneal shunt for idiopathic normal pressure hydrocephalus (iNPH) implanted 4 years earlier showed progressive parkinsonism for the past year. His clinical symptoms, including resting tremor and rapid eye movement sleep behavior disorder, responsiveness to levodopa, and abnormal findings on I-MIBG myocardial scintigraphy and dopamine transporter imaging, indicated that his pathological background of parkinsonism included concomitant synucleinopathy, such as Parkinson's disease or dementia with Lewy bodies, in addition to iNPH. Clinicians should consider the possibility of concomitant proteinopathies and their treatments when clinical symptoms become evident after shunt operations in patients with iNPH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.4553-20DOI Listing

Synucleinphagy: a microglial "community cleanup program" for neuroprotection.

Autophagy 2020 Jun 9:1-3. Epub 2020 Jun 9.

Departments of Neurology and Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai , New York, NY, USA.

SNCA/α-synuclein is a major component in the Lewy body (LB), a pathological hallmark of Parkinson disease (PD) and dementia with Lewy body (DLB), collectively known as synucleinopathies. SNCA/α-synuclein can be secreted from neurons and transmitted to neighboring cells including neurons and glia, which underlie the spreading of LB pathology as described by Braak and colleagues. We recently have investigated the mechanism and significance for microglia, a prototypic phagocyte in the brain, in engulfing and controlling SNCA/α-synuclein homeostasis in the brain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15548627.2020.1774149DOI Listing

Restoration of CTSD (cathepsin D) and lysosomal function in stroke is neuroprotective.

Autophagy 2020 May 25:1-19. Epub 2020 May 25.

Department of Pharmacology and Toxicology, University of Alabama at Birmingham School of Medicine , Birmingham, AL, USA.

Stroke is a leading cause of death and disability. The pathophysiological mechanisms associated with stroke are very complex and not fully understood. Lysosomal function has a vital physiological function in the maintenance of cellular homeostasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15548627.2020.1761219DOI Listing

Should We Consider Deep Brain Stimulation Discontinuation in Late-Stage Parkinson's Disease?

Mov Disord 2020 May 25. Epub 2020 May 25.

Department of Neuroscience "Rita Levi Montalcini,", University of Torino, Turin, Italy.

Background: Subthalamic deep brain stimulation (STN-DBS) effects may decrease with Parkinson's disease (PD) progression. There is no indication if, when, and how to consider the interruption of DBS treatment in late-stage PD. The objective of the current study was to investigate the percentage of "poor stimulation responders" among late-stage PD patients for elaborating an algorithm to decide whether and when DBS discontinuation may be considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.28091DOI Listing

Overview of sleep disturbances and their management in Parkinson plus disorders.

J Neurol Sci 2020 May 8;415:116891. Epub 2020 May 8.

Department of Neurology, National Institute of Mental Health & Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka 560029, India. Electronic address:

Sleep disturbance is one of the commonly reported non-motor symptoms in patients with Parkinson's disease (PD) as well as in Parkinson plus disorders such as multiple system atrophy (MSA), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS). Although there is a wealth of literature on sleep disturbances in PD, the same is not robust on the Parkinson plus disorders. This article aims to comprehensively review the sleep disturbances in Parkinson plus disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2020.116891DOI Listing

Lewy Body Degenerations as Neuropsychiatric Disorders.

Psychiatr Clin North Am 2020 Jun 8;43(2):361-381. Epub 2020 Apr 8.

Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, 600 North Wolfe Street, Phipps 300, Baltimore, MD 21287, USA; Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA. Electronic address:

Parkinson disease has historically been conceptualized as a movement disorder. In recent decades, nonmotor and neuropsychiatric symptoms have become increasingly recognized as being of paramount importance for patients with Parkinson disease. Neuropsychiatric phenomena dominate the course of the other major Lewy body disease, dementia with Lewy bodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psc.2020.02.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245581PMC

Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases.

Cells 2020 05 19;9(5). Epub 2020 May 19.

Molecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Science Park of Barcelona, 08028 Barcelona, Spain.

Reelin is an extracellular glycoprotein that modulates neuronal function and synaptic plasticity in the adult brain. Decreased levels of Reelin activity have been postulated as a key factor during neurodegeneration in Alzheimer´s disease (AD) and in aging. Thus, changes in levels of full-length Reelin and Reelin fragments have been revealed in cerebrospinal fluid (CSF) and in post-mortem brains samples of AD patients with respect to non-AD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells9051252DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290479PMC

DCTN1-related Parkinson-plus disorder (Perry syndrome).

Pract Neurol 2020 May 20. Epub 2020 May 20.

Department of Neurology, St George's Hospital, London, UK

Dynactin-1 (DCTN1)-related Parkinson-plus disorder (Perry syndrome) is an autosomal dominant neurodegenerative disorder characterised by levodopa-resistant parkinsonism, weight loss, mood change and central hypoventilation. Ventilatory insufficiency is the predominant cause of death. It has been previously described in 87 people from 20 families with a worldwide distribution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/practneurol-2020-002505DOI Listing

Neurogeriatrics-a vision for improved care and research for geriatric patients with predominating neurological disabilities.

Z Gerontol Geriatr 2020 Jul 19;53(4):340-346. Epub 2020 May 19.

Department of Neurology, University Hospital Schleswig-Holstein Campus Kiel, Kiel University, Arnold-Heller-Str. 3, House D, 24105, Kiel, Germany.

Geriatric medicine is a rapidly evolving field that addresses diagnostic, therapeutic and care aspects of older adults. Some disabilities and disorders affecting cognition (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00391-020-01734-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311516PMC
July 2020
1.023 Impact Factor

Dietary Factors and Neurodegenerative Disorders: An Umbrella Review of Meta-Analyses of Prospective Studies.

Adv Nutr 2020 May 19. Epub 2020 May 19.

Department of Nutrition and Food Sciences, Nutritional Epidemiology, University of Bonn, Bonn, Germany.

Diet has been hypothesized to be associated with neurodegenerative disorders. The aim was to conduct an umbrella review to summarize and evaluate the current evidence of prospective associations between any dietary factors and the incidence of neurodegenerative disorders. We conducted a systematic search in PubMed, Embase, and the Cochrane library up to November 2019 to identify systematic reviews with meta-analyses of prospective studies investigating the association between dietary factors (dietary patterns, foods and beverages, nutrients, and phytochemicals) and neurodegenerative disorders (cognitive decline, cognitive impairment, Alzheimer disease, all-cause dementia, and Parkinson disease). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/advances/nmaa053DOI Listing

The emerging role of α-synuclein truncation in aggregation and disease.

J Biol Chem 2020 05 18. Epub 2020 May 18.

University of Florida, United States.

α-synuclein (αsyn) is an abundant, brain neuronal protein that can misfold and polymerize to form toxic fibrils coalescing into pathologic inclusions in neurodegenerative diseases including Parkinson's disease (PD), Lewy body dementia (LBD), and multiple system atrophy (MSA). These fibrils may induce further αsyn misfolding and propagation of pathologic fibrils in a prion-like process. It is unclear why αsyn initially misfolds, but a growing body of literature suggests a critical role of partial proteolytic processing resulting in various truncations of the highly charged and flexible carboxy-terminal region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.REV120.011743DOI Listing

Human brain connectivity: Clinical applications for clinical neurophysiology.

Clin Neurophysiol 2020 Jul 21;131(7):1621-1651. Epub 2020 Apr 21.

Department of Neuroscience and Neurorehabilitation, Brain Connectivity Laboratory, IRCCS San Raffaele Pisana, Rome, Italy.

This manuscript is the second part of a two-part description of the current status of understanding of the network function of the brain in health and disease. We start with the concept that brain function can be understood only by understanding its networks, how and why information flows in the brain. The first manuscript dealt with methods for network analysis, and the current manuscript focuses on the use of these methods to understand a wide variety of neurological and psychiatric disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinph.2020.03.031DOI Listing
July 2020
3.097 Impact Factor

Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease.

Mov Disord 2020 Jun 4;35(6):1062-1066. Epub 2020 Mar 4.

John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.

Introduction: Immune markers are altered in Parkinson's disease (PD), but relationships between cerebrospinal fluid (CSF) and plasma cytokines and associations with neurodegeneration-associated proteins remain unclear.

Methods: CSF and plasma samples and demographic/clinical measures were obtained from 35 PD patients. CSF samples were analyzed for cytokines (together with plasma) and for α-synuclein, amyloid β(1-42) peptide, total tau, and phospho(Thr231)-tau. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.28015DOI Listing

Is There Any Clinical Value of Adding 123I-Metaiodobenzylguanidine Myocardial Scintigraphy to 123I-Ioflupane (DaTscan) in the Differential Diagnosis of Parkinsonism?

Clin Nucl Med 2020 Aug;45(8):588-593

Department of Neurology, University Hospital, Heraklion, Crete, Greece.

Purpose: The aim of the study is to evaluate the impact of myocardial I-metaiodobenzylguanidine (MIBG) in the diagnosis, clinical management, and differential diagnosis of Parkinson disease (PD) and non-PD parkinsonism.

Methods: The study enrolled 41 patients with parkinsonism. An initial diagnosis was reached after thorough clinical and imaging evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003098DOI Listing

Clinical trials in REM sleep behavioural disorder: challenges and opportunities.

J Neurol Neurosurg Psychiatry 2020 Jul 13;91(7):740-749. Epub 2020 May 13.

Paracelsus Elena Klinik, Kassel, Germany.

The rapid eye movement sleep behavioural disorder (RBD) population is an ideal study population for testing disease-modifying treatments for synucleinopathies, since RBD represents an early prodromal stage of synucleinopathy when neuropathology may be more responsive to treatment. While clonazepam and melatonin are most commonly used as symptomatic treatments for RBD, clinical trials of symptomatic treatments are also needed to identify evidence-based treatments. A comprehensive framework for both disease-modifying and symptomatic treatment trials in RBD is described, including potential treatments in the pipeline, cost-effective participant recruitment and selection, study design, outcomes and dissemination of results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2020-322875DOI Listing

Understanding the role of social cognition in neurodegenerative Disease: A scoping review on an overlooked problem.

J Clin Neurosci 2020 Jul 7;77:17-24. Epub 2020 May 7.

IRCCS Centro Neurolesi "Bonino Pulejo", Messina, Italy. Electronic address:

Social cognition (SC) is the set of socio-cognitive processes that guide automatic and voluntary behaviors by modulating behavioral responses, it includes both cognitive (Theory of the mind - ToM) and affective aspects (Empathy). SC also includes representations of internal somatic states, self-knowledge, perception of others, communication with others and interpersonal motivations. SC is relevant in daily life and reflects the neural complexity of social processing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2020.05.013DOI Listing

PLA2G4E, a candidate gene for resilience in Alzheimer´s disease and a new target for dementia treatment.

Prog Neurobiol 2020 Aug 5;191:101818. Epub 2020 May 5.

Alzheimer´s Disease, Neurosciences Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain; IdiSNA (Navarra Institute for Health Research) Pamplona, Spain. Electronic address:

Clinical studies revealed that some aged-individuals accumulate a significant number of histopathological Alzheimer´s disease (AD) lesions in their brain, yet without developing any signs of dementia. Animal models of AD represent suitable tools to identify genes that might promote cognitive resilience and hence, this study first set out to identify cognitively resilient individuals in the aged-Tg2576 mouse model. A transcriptomic analysis of these mice identified PLA2G4E as a gene that might confer resistance to dementia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pneurobio.2020.101818DOI Listing